CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...

CSL Limited trades at a decade-low P/E, despite ongoing revenue and profit growth, presenting significant upside potential. CSL's vaccine business volatility and slow margin recovery, especially at ...

Cathy Hackl is a globally recognized tech & gaming executive, futurist, author and keynote speaker who focuses on Spatial Computing, virtual worlds, AR, AI, world models, spatial AI, tech trends, ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Good afternoon, everyone, and thank you for joining us on short notice. My name is Mark Dehring, Head of Investor Relations at CSL. The focus of today's call is CSL's leadership transition, and we ...

CSL’s interim chief executive Gordon Naylor has pleaded with angry investors for more time to return the global healthcare giant to its former glory, saying he will look at selling or scaling back non ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Cathy Applefeld Olson is a veteran entertainment industry journalist with more than 30 years experience covering music, television, film, digital and culture. Cathy’s current passion is the ...

CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...

SYDNEY--Shares of pharmaceutical company CSL fell early Wednesday as investors react to the sudden departure of chief executive Paul McKenzie and an 80% fall in first-half net profit. The stock was ...

The worst US flu season in decades did not shield one of Australia’s largest companies, biotechnology firm CSL, from another brutal market response as vaccine scepticism from Trump administration ...